Rédaction Africa Links 24 with Meghana Keshavan
Published on 2024-03-15 13:09:26
Biotechnology is an ever-evolving field with new advancements and approvals happening all the time. Stay informed with our biotech newsletter for the latest updates on the science and politics driving the industry.
Today, we have some exciting news to share. Bristol Myers Squibb has secured FDA approval to expand the use of its Breyanzi CAR-T treatment to include patients with chronic lymphocytic leukemia, a significant breakthrough in personalized cell therapy for blood cancer.
Madrigal Pharmaceuticals has also received accelerated approval from the FDA for Rezdiffra, the first drug to treat MASH – a serious liver disease associated with obesity. This approval is contingent on ongoing studies to determine the drug’s long-term effects, but initial results show promising outcomes for patients.
In other news, Sangamo Therapeutics, a pioneer in gene editing technologies, is facing financial difficulties with a cash crunch looming on the horizon. Despite promising technologies in their pipeline, the company’s expenses may outpace its revenue, raising concerns about its future viability in the market.
On the topic of drug efficacy, our biotech podcast, “The Readout LOUD,” explores the challenges and implications when approved drugs do not deliver the expected results. Bioethicist Holly Fernandez Lynch joins the discussion on the case of Amylyx Pharmaceuticals’ ALS treatment and its implications for drug development.
Gilead’s antiviral drug, Obeldesivir, has shown promising results in treating Ebola Sudan infections, offering a potential game-changer in the fight against this deadly disease. Unlike existing treatments, Obeldesivir is taken in pill form and is easier to distribute and store, making it a more accessible option for combating Ebola outbreaks.
Furthermore, an FDA advisory committee has recommended Geron’s drug, imetelstat, for the treatment of transfusion-dependent anemia in patients with myelodysplastic syndromes. Despite safety concerns, the benefits of the treatment outweigh the risks, and regulators are expected to make a decision in the coming months.
As the biotech industry continues to advance, it is essential to stay informed on the latest developments and breakthroughs. Join our secret list for an upcoming biotech newsletter to receive exclusive content and insights into the future of biotechnology. Stay ahead of the curve with our biotech newsletter.
